glp-1 gip therapies muscle preservation combination 2025 Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response Application of nutrition interventions with

Diabetes Care (2016) 39:12419

The accumulated evidence over recent decades regarding the efficacy of new pharmacological treatments for obesity has positioned the glucagon-like peptide-1 (GLP-1) analogue as a key componentwhether as monoagonists, unimolecular multiagonists, or in combination therapies targeting multiple receptors.1 These drugs have made it possible to achieve previously unthinkable goals in terms of weight reduction and control of various obesity-related comorbidities (Fig

Hieronymus L, Griffin S

& Merad, M

PubMed Discontinuing glucagon-like peptide-1 receptor agonists and body habitus Used for pages discussing stopping therapy, weight regain, and long-term planning

10.1016/j.cgh.2008.11.022 23